Evidence map›Paper›PMID 40051948›Full record

ArticleCureus2025

Prevalence of Somatic BReast CAncer Gene (BRCA) 1 and 2 Pathogenic Variants in Portuguese Metastatic Prostate Cancer Patients.

Tiago Barroso, Carolina Monteiro, Vanessa Patel, Lisa Gonçalves, Ana Rita Sousa, Raquel Lopes Brás, André Mansinho, Mariana Soeiro E Sá, Ana Sousa, Luís Costa

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Tiago BarrosoMedical Oncology, Unidade Local de Saude (ULS) Santa Maria, Lisbon, PRT.
Carolina MonteiroMedical Oncology, Unidade Local de Saude (ULS) Santa Maria, Lisbon, PRT.
Vanessa PatelMedical Oncology, Unidade Local de Saude (ULS) Santa Maria, Lisbon, PRT.
Lisa GonçalvesMedical Oncology, Unidade Local de Saude (ULS) Santa Maria, Lisbon, PRT.
Ana Rita SousaMedical Oncology, Unidade Local de Saude (ULS) Santa Maria, Lisbon, PRT.
Raquel Lopes BrásMedical Oncology, Unidade Local de Saude (ULS) Santa Maria, Lisbon, PRT.
André MansinhoSTART Lisbon, Unidade Local de Saude (ULS) Santa Maria, Lisbon, PRT.
Mariana Soeiro E SáMedical Genetics, Unidade Local de Saude (ULS) Santa Maria, Lisbon, PRT.
Ana SousaMedical Genetics, Unidade Local de Saude (ULS) Santa Maria, Lisbon, PRT.
Luís CostaMedical Oncology, Unidade Local de Saude (ULS) Santa Maria, Lisbon, PRT.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Currently, poly adenosine diphosphate ribose polymerase inhibitors are used to treat metastatic prostate cancer (mPC) patients with somatic or germline pathogenic variants in genes related to homologous recombination repair deficiency. Testing for these variants is thus advisable, as test results can have implications for systemic treatment. Of those genes, the most relevant in clinical practice are BReast CAncer gene (

Indexed as

brca1/2 mutationseuropemetastatic prostate cancerparp inhibitorsportugalprostate cancer

Identifiers

PMID40051948
PMCPMC11884503

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.